New Cancer Medicine Test

There is a chance for the scientists from Hamburg to receive more effective drug developed against cancer. As per the speech by Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, there is the development of Pre-Clinical Trial Platform of a certain drug testing to analyze tumor tissue in patient on molecular level of the drug response.Mostly, there used liver, kidney or lung tissue slices to test metabolism and toxicity of drugs. The new trial is applied on usage of colorectal and lung cancer patients' tumor tissues.Nowadays the scientists are dumped with the issue in preclinical trials of patients' cell models as a extrapolate response. Dr. Schonn explained that about 90% of clinical tests were failed with the reason of toxicity of ineffectiveness of the examined drugs. And the issue is not only in high cost of the research in the drug development but high risk given by toxicity to the patients and even the patients' time spending for the testing that gave ineffective response.All of this is because of individualism in the patients' response to the examined drug. Moreover, non-tumor cells interact with tumor ones in different ways, where the tumor cells included differ kinds of cancer cells, and as result there was widely different growth of the tested drug behavior and response. So, Dr. Schonn and her group made a step to find a solution in presenting a certain model of tested patients' as sole response. Dr. Schonn believed that her group of scientists could analyze variety of tumors taken from operated patients and could confirm the differences in the tested drug response to clarify the response variety in cells subtypes within a tumor. All these studies would be based on taking freshly cultivates intact tissue from operated cancer patients.This specific trial gives a chance for the scientists to analyze and clarify results taken from regular cells in comparison with preclinical model that is the closest in the same drug usage in the clinical trials. The purpose is to estimate more precisely patients quantity responded to the treatment and to identify bio markers predicted the clinical patients' drug response to select only the patients whose participation would be highly effective to reply on the trial subject. There is possibility to identify tumors individually in all details based on data base of the clinical patients and some analytical testing systems as signal analysis."We could receive improved results of the drug effectiveness and treatments methods in individualization of cancer therapy. Pharmaceutical companies are mostly interested in this particular study as the analytical results shall be given in a short time so that there is capability for progressive acceleration of new treatment in clinical tests", added Dr. Schonn.Moreover, it gives more information regarding action mode of new drug in patients and identifies illness area optimization like certain mutation or over-action of target receptors and doses.The scientists believe that the test would be valid in breast cancer tumors, colon, and medium and large sized lung cells so that could not be accurately equal to other solid tumor types because the trial gives an opportunity to fix the primary cancer tumor complex environment and it would lead to fast and effective response elucidation to anti-cancer medicines. Dr. Schonn added that there are expectations to administer growing number of drugs from pharmaceutical companies' labs to shorten development period of time and to do clinical testing as effective and safe for the patients.